Compare Ascendis Pharma A/S (ASND) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Live Nation Entertainment, Inc. — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Live Nation Entertainment, Inc. trades at $179.47 (market cap $41.84B). The key difference: Live Nation Entertainment, Inc. is far larger — about 2.4× Ascendis Pharma A/S's market cap. Which is the better fit depends on your goals.
| ASND | LYV | |
|---|---|---|
Market Cap | $17.74B | $41.84B |
Sector | Health | Industrials |
52-Week High | $277.18 | $186.59 |
52-Week Low | $163.32 | $125.61 |
Enterprise Value | $18.11B | $43.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Live Nation (LYV) trades at $179.79, down 1.53% today, with strong analyst support (88.6% buy ratings) and a $200.20 consensus price target. The stock shows bullish technical signals despite recent earnings misses, with revenue growth to $25.2B in 2025 but net margins narrowing to 1.96%. Recent news highlights strong concert demand and strategic initiatives, though legal challenges and cost pressures remain concerns.
Outlook remains positive based on analyst consensus and projected cash flow growth, but investors face risks from volatile earnings, high debt levels, and regulatory scrutiny. The stock's elevated P/E of 117.5 reflects growth expectations that must materialize to justify current valuations amid competitive and economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
